<DOC>
	<DOC>NCT02243150</DOC>
	<brief_summary>This first-in-human (FIH) study will provide the first safety, PK, and PD data of G1T28-1 in humans and will allow further development of G1T28 1 in patients with cancer to reduce chemotherapy-induced myelosuppression.</brief_summary>
	<brief_title>Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1</brief_title>
	<detailed_description />
	<criteria>Healthy male and female volunteers, 1860 years of age; no clinically significant findings reported following detailed physical examination, medical history, vital signs, clinical laboratory tests, and ECGs as deemed by the PI Body mass index (BMI) in the range of 18 to 32 kg/m2 (inclusive) and weighing at least 50 kg Nonsmokers / nonusers of nicotine containing products for at least the previous 3 months Agreement to use birth control during the study and 3 months post last visit Able to comply with all protocol requirements and procedures Clinically significant abnormalities found during physical examination, medical history review, ECGs (including QTcf interval &gt; 450 msec), vital signs and laboratory tests (including positive test for HIV, hepatitis B and/or C) History of any serious allergic reaction to any medication Participated in a previous clinical trial with an investigational product in the last 60 days Any blood or plasma donation or other loss of blood at a volume exceeding 500 mL within 3 months before dosing History of drug or alcohol abuse in the last 2 years and positive test for drug abuse Use of any systemic medication within the past 2 weeks, including use of herbal products Pregnant or lactating women Any other issue which, in the opinion of the PI, will make the subject ineligible for study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>